13725-38-7 Usage
Description
Cyclopentanol,3-amino-(7CI,8CI,9CI), also known as 3-Aminocyclopentanol, is an organic compound with the chemical formula C5H11NO. It is a derivative of cyclopentanol, featuring an amino group attached to the third carbon atom. Cyclopentanol,3-amino-(7CI,8CI,9CI) has potential applications in various industries due to its unique chemical properties.
Uses
Used in the Golf Ball Industry:
Cyclopentanol,3-amino-(7CI,8CI,9CI) is used as a modifying agent for acidic polymers in the golf ball industry. Its incorporation into the polymer matrix enhances the performance characteristics of golf balls, such as durability, resilience, and overall playability.
Used in the Automotive Industry:
Cyclopentanol,3-amino-(7CI,8CI,9CI) is used as a detergent in the automotive industry, specifically for diesel fuel and gasoline. Its addition to fuel formulations helps in cleaning and maintaining the engine components, leading to improved engine performance, reduced emissions, and extended engine life.
Check Digit Verification of cas no
The CAS Registry Mumber 13725-38-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,3,7,2 and 5 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 13725-38:
(7*1)+(6*3)+(5*7)+(4*2)+(3*5)+(2*3)+(1*8)=97
97 % 10 = 7
So 13725-38-7 is a valid CAS Registry Number.
13725-38-7Relevant articles and documents
KRAS G12C Inhibitor compound and application thereof
-
Paragraph 0141-0142; 0146-0148, (2021/05/12)
The invention provides a KRAS G12C inhibitor compound and an application thereof, and particularly provides a compound as shown in a formula (I), and an optical isomer, a hydrate, a solvate or pharmaceutically acceptable salt thereof. The compound can be used as a KRAS G12C inhibitor and is used for treating diseases related to the activity or expression quantity of KRAS G12C.
Compounds specific to adenosine A1 receptors and uses thereof
-
, (2008/06/13)
This invention pertains to compounds which specifically inhibit the adenosine A1 receptor and the use of these compounds to treat a disease associated with A1 adenosine receptors in a subject.